Silence Therapeutics (NASDAQ:SLN) Sees Strong Trading Volume - Should You Buy?

Key Points

• Silence Therapeutics saw unusually heavy trading activity, with volume rising 32% to about 719,539 shares and call-option purchases far exceeding average levels, signaling heightened investor interest.
• Analyst sentiment is generally positive: HC Wainwright maintained a Buy rating and $75 target, while the consensus rating is Moderate Buy with a $53.50 target. However, targets vary widely, including a Sell rating from Weiss Ratings.
• The company remains unprofitable and recently missed quarterly EPS expectations, reporting a $0.26 loss versus the $0.14 expected loss. Forecasts point to narrower future losses, but near-term execution and valuation risks remain.

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN - Get Free Report) saw unusually-strong trading volume on Tuesday . Approximately 719,539 shares were traded during trading, an increase of 32% from the previous session's volume of 543,220 shares.The stock last traded at $14.14 and had previously closed at $14.35.

Key Headlines Impacting Silence Therapeutics

Here are the key news stories impacting Silence Therapeutics this week:

• Positive Sentiment: HC Wainwright raised most of its earnings forecasts for Silence Therapeutics, including FY2026 EPS to $(1.14) from $(1.38), FY2027 EPS to $(1.38) from $(1.74), FY2028 EPS to $(1.53) from $(1.65), and FY2030 EPS to $(1.50) from $(1.77). The firm also improved estimates for each quarter from Q3 2026 through Q4 2027, indicating expectations for narrower losses than previously projected.
• Positive Sentiment: HC Wainwright maintained its Buy rating and $75 price target. With SLN recently trading near $14, the target implies substantial potential upside if the company meets the analyst’s longer-term expectations.
• Positive Sentiment: Unusual options activity added a bullish signal: investors purchased 24,155 call options, compared with average daily call volume of 555. Heavy call buying can indicate expectations for additional share-price gains, although it is not confirmation of future performance.
• Neutral Sentiment: Silence Therapeutics is still expected to report losses, with consensus full-year EPS at $(1.08) and HC Wainwright forecasting $(1.14) for FY2026. The revised estimates represent improving loss expectations rather than near-term profitability.
• Negative Sentiment: HC Wainwright lowered its FY2029 EPS forecast to $(1.92) from $(1.74), showing that the long-term outlook is not uniformly improving. The company also recently missed quarterly EPS expectations, underscoring execution and valuation risk.

Wall Street Analyst Weigh In

Several research firms have commented on SLN. Cantor Fitzgerald started coverage on shares of Silence Therapeutics in a research note on Wednesday, June 24th. They set an "overweight" rating for the company. HC Wainwright reissued a "buy" rating and issued a $75.00 target price on shares of Silence Therapeutics in a research note on Wednesday, June 17th. Weiss Ratings restated a "sell (d-)" rating on shares of Silence Therapeutics in a report on Friday, July 17th. Finally, Morgan Stanley lifted their price target on shares of Silence Therapeutics from $25.00 to $32.00 and gave the stock an "overweight" rating in a research note on Tuesday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Silence Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $53.50.

Silence Therapeutics Price Performance

The stock has a market capitalization of $659.57 million, a PE ratio of -10.90 and a beta of 1.39. The firm has a fifty day moving average price of $10.26 and a two-hundred day moving average price of $7.55.

Silence Therapeutics (NASDAQ:SLN - Get Free Report) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.12). Silence Therapeutics had a negative net margin of 8,943.86% and a negative return on equity of 106.94%. On average, research analysts expect that Silence Therapeutics PLC Sponsored ADR will post -1.08 earnings per share for the current fiscal year.

Institutional Trading of Silence Therapeutics

A number of large investors have recently made changes to their positions in the stock. Nantahala Capital Management LLC increased its stake in Silence Therapeutics by 48.0% in the 4th quarter. Nantahala Capital Management LLC now owns 1,542,427 shares of the company's stock worth $9,378,000 after buying an additional 500,000 shares during the period. Millennium Management LLC boosted its position in Silence Therapeutics by 121.0% in the 4th quarter. Millennium Management LLC now owns 659,592 shares of the company's stock valued at $4,010,000 after buying an additional 361,080 shares during the period. 5AM Venture Management LLC purchased a new stake in Silence Therapeutics in the 2nd quarter valued at about $5,228,676,000. UBS Group AG grew its stake in Silence Therapeutics by 34.5% in the 3rd quarter. UBS Group AG now owns 307,363 shares of the company's stock worth $1,595,000 after acquiring an additional 78,854 shares in the last quarter. Finally, SG Americas Securities LLC grew its stake in Silence Therapeutics by 11.8% in the 1st quarter. SG Americas Securities LLC now owns 286,698 shares of the company's stock worth $1,511,000 after acquiring an additional 30,358 shares in the last quarter. 98.73% of the stock is owned by hedge funds and other institutional investors.

Silence Therapeutics Company Profile

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence's technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company's lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source